Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: Feasibility and future requirements

Clinical Infectious Diseases

Volumn 57, Issue 7, 2013, Pages 1014-1020

  Grebely, Jason ^a   Matthews, Gail V ^a   Lloyd, Andrew R ^b   Dore, Gregory J ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Drug users; HCV; HIV; Injection; Modeling

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; DIRECT ACTING ANTIVIRAL AGENT; PEGINTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG;

ANTIVIRAL THERAPY; ARTICLE; CANCER RISK; COST EFFECTIVENESS ANALYSIS; FEASIBILITY STUDY; HEALTH CARE COST; HEALTH CARE DELIVERY; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; LIVER CELL CARCINOMA; MATHEMATICAL MODEL; MORBIDITY; MORTALITY; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; SCREENING; TREATMENT RESPONSE; VIRUS TRANSMISSION;

DRUG USERS; HCV; HIV; INJECTION; MODELING;

ANTIVIRAL AGENTS; DISEASE ERADICATION; HEPATITIS C; HUMANS; MODELS, THEORETICAL; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84884365834     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit377     Document Type: Article

References (95)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5:558-67.
2. Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011; 378:571-83.
3. Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet 2010; 376:285-301.
4. Hagan H, Pouget ER, Des Jarlais DC. A systematic review and metaanalysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis 2011; 204:74-83.
5. Sacks-Davis R, Horyniak D, Grebely J, Hellard M. Behavioural interventions for preventing hepatitis C infection in people who inject drugs: A global systematic review. Int J Drug Policy 2012; 23:176-84.
6. Turner KM, Hutchinson S, Vickerman P, et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction 2011; 106:1978-88.
7. Mathers BM, Degenhardt L, Ali H, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 2010; 375:1014-28.
8. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156:271-8.
9. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a metaanalysis and meta-regression. Hepatology 2008; 48:418-31.
10. Grebely J, Dore GJ. What is killing people with hepatitis C virus infection? Semin Liver Dis 2011; 31:331-9.
11. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009; 49:561-73.
12. NCHECR. HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report. National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, 2009.
13. Mehta SH, Genberg BL, Astemborski J, et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008; 33:126-33.
14. Grebely J, Raffa JD, Lai C, et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat 2009; 16:352-8.
15. Strathdee SA, Latka M, Campbell J, et al. Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users. Clin Infect Dis 2005; 40(Suppl 5):S304-12.
16. Dore GJ. The changing therapeutic landscape for hepatitis C. Med J Aust 2012; 196:629-32.
17. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
18. Durier N, Nguyen C, White LJ. Treatment of hepatitis C as prevention: a modeling case study in Vietnam. Plos One 2012; 7:e34548.
19. Hellard ME, Jenkinson R, Higgs P, et al. Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia. Med J Aust 2012; 196:638-41.
20. Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol 2011; 54:1137-44.
21. Martin NK, Vickerman P, Hickman M. Mathematical modelling of hepatitis C treatment for injecting drug users. J Theor Biol 2011; 274: 58-66.
22. Martin NK, Pitcher AB, Vickerman P, Vassall A, Hickman M. Optimal control of hepatitis C antiviral treatment programme delivery for prevention amongst a population of injecting drug users. Plos One 2011; 6:e22309.
23. Matser A, Urbanus A, Geskus R, et al. The effect of hepatitis C treatment and human immunodeficiency virus (HIV) co-infection on the disease burden of hepatitis C among injecting drug users in Amsterdam. Addiction 2012; 107:614-23.
24. Vickerman P, Martin N, Hickman M. Can Hepatitis C virus treatment be used as a prevention strategy? Additional model projections for Australia and elsewhere. Drug Alcohol Depend 2011; 113:83-5; discussion 6-7.
25. Zeiler I, Langlands T, Murray JM, Ritter A. Optimal targeting of Hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs. Drug Alcohol Depend 2010; 110:228-33.
26. Editorial THMCTaP, Group W. HIV treatment as prevention: models, data, and questions-towards evidence-based decision-making. PLoS Med 2012; 9:e1001259.
27. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006; 13:34-41.
28. van den Berg CH, Smit C, Bakker M, et al. Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. Eur J Epidemiol 2007; 22:183-93.
29. Mehta SH, Astemborski J, Kirk GD, et al. Changes in blood-borne infection risk among injection drug users. J Infect Dis 2011; 203:587-94.
30. Patrick DM, Tyndall MW, Cornelisse PG, et al. Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. Cmaj 2001; 165:889-95.
31. Maher L, Li J, Jalaludin B, Chant KG, Kaldor JM. High hepatitis C incidence in new injecting drug users: a policy failure? Aust N Z J Public Health 2007; 31:30-5.
32. Miller CL, Strathdee SA, Spittal PM, et al. Elevated rates of HIV infection among young Aboriginal injection drug users in a Canadian setting. Harm Reduct J 2006; 3:9.
33. Kim C, Kerr T, Li K, et al. Unstable housing and hepatitis C incidence among injection drug users in a Canadian setting. BMC Public Health 2009; 9:270.
34. Miller CL, Johnston C, Spittal PM, et al. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology 2002; 36:737-42.
35. Roy E, Alary M, Morissette C, et al. High hepatitis C virus prevalence and incidence among Canadian intravenous drug users. Int J STD AIDS 2007; 18:23-7.
36. Bruneau J, Daniel M, Kestens Y, Abrahamowicz M, Zang G. Availability of body art facilities and body art piercing do not predict hepatitis C acquisition among injection drug users in Montreal, Canada: Results from a cohort study. Int J Drug Policy 2010; 21:477-84.
37. Aitken C, Lewis J, Hocking J, Bowden DS, Hellard M. Does Information about IDUs' Injecting Networks Predict Exposure to the Hepatitis C Virus? Hepatitis Monthly 2009; 9:17-23.
38. Hagan H, Thiede H, Des Jarlais DC. Hepatitis C virus infection among injection drug users: survival analysis of time to seroconversion. Epidemiology 2004; 15:543-9.
39. Roy E, Boudreau JF, Boivin JF. Hepatitis C virus incidence among young street-involved IDUs in relation to injection experience. Drug Alcohol Depend 2009; 102:158-61.
40. Palmateer N, Kimber J, Hickman M, Hutchinson S, Rhodes T, Goldberg D. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Addiction 2010; 105:844-59.
41. Van Den Berg C, Smit C, Van Brussel G, Coutinho R, Prins M. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction 2007; 102:1454-62.
42. Kiyosawa K, Sodeyama T, Tanaka E, et al. Hepatitis C in hospital employees with needlestick injuries. Ann Intern Med 1991; 115: 367-9.
43. MacDonald M, Crofts N, Kaldor J. Transmission of hepatitis C virus: rates, routes, and cofactors. Epidemiol Rev 1996; 18:137-48.
44. Sodeyama T, Kiyosawa K, Urushihara A, et al. Detection of hepatitis C virus markers and hepatitis C virus genomic-RNA after needlestick accidents. Arch Intern Med 1993; 153:1565-72.
45. Moloughney BW. Transmission and postexposure management of bloodborne virus infections in the health care setting: where are we now? CMAJ 2001; 165:445-51.
46. Kaplan EH, Heimer R. A model-based estimate of HIV infectivity via needle sharing. J Acquir Immune Defic Syndr 1992; 5: 1116-8.
47. Henderson DK, Fahey BJ, Willy M, et al. Risk for occupational transmission of human immunodeficiency virus type 1 (HIV-1) associated with clinical exposures. A prospective evaluation. Ann Intern Med 1990; 113:740-6.
48. Hudgens MG, Longini IM Jr, Vanichseni S, et al. Subtype-specific transmission probabilities for human immunodeficiency virus type 1 among injecting drug users in Bangkok, Thailand. Am J Epidemiol 2002; 155:159-68.
49. Seeff LB. The history of the "natural history" of hepatitis C (1968-2009). Liver Int 2009; 29(Suppl 1):89-99.
50. Grebely J, Prins M, Hellard M, et al. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis 2012; 12:408-14.
51. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008; 22:1979-91.
52. Amin J, Law MG, Bartlett M, Kaldor JM, Dore GJ. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large communitybased linkage study. Lancet 2006; 368:938-45.
53. Grebely J, Tyndall MW. Management of HCV and HIV infections among people who inject drugs. Current Opinions in HIV/AIDS 2011; 6:501-7.
54. Kramer JR, Kanwal F, Richardson P, Giordano TP, Petersen LA, El-Serag HB. Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study. Am J Gastroenterol 2011; 106:483-91.
55. Gidding HF, Law MG, Amin J, et al. Predictors of deferral of treatment for hepatitis C infection in Australian clinics. Med J Aust 2011; 194:398-402.
56. Conway B, Grebely J, Tossonian H, Lefebvre D, de Vlaming S. A systematic approach to the treatment of HIV and hepatitis C virus infection in the inner city: a Canadian perspective. Clin Infect Dis 2005; 41(Suppl 1):S73-8.
57. Bini EJ, Brau N, Currie S, et al. Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol 2005; 100:1772-9.
58. Kanwal F, Hoang T, Spiegel BM, et al. Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors. Hepatology 2007; 46:1741-9.
59. NCHECR. Australian NSP Survey National Data Report 2005-2009. Sydney, NSW: National Centre in HIV Epidemiology and Clinical Research, The University of New SouthWales, 2010.
60. Australian NSP survey National Data Report 1995-2010. Faculty of Medicine, The Kirby Institute for infection and immunity in Society, University of New SouthWales, 2011.
61. NCHECR. Epidemiological and economic impact of potential increased hepatitis C treatment uptake in Australia. National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, 2010.
62. Lettmeier B, Muhlberger N, Schwarzer R, et al. Market uptake of new antiviral drugs for the treatment of hepatitis C. J Hepatol 2008; 49: 528-36.
63. Volk ML, Tocco R, Saini S, Lok AS. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 2009; 50:1750-5.
64. Aspinall E, Corson S, Doyle J, et al. Peginterferon and ribavirin treatment for chronic hepatitis C virus in people who inject drugs: A systematic review and meta-analysis. Clin Infect Dis 2012; 57(Suppl 2): S80-9.
65. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49:1335-74.
66. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55:245-64.
67. Backmund M, Meyer K, Edlin BR. Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis 2004; 39:1540-3.
68. Dalgard O. Follow-up studies of treatment for hepatitis C virus infection among injection drug users. Clin Infect Dis 2005; 40(Suppl 5):S336-8.
69. Currie SL, Ryan JC, Tracy D, et al. A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus. Drug Alcohol Depend 2008; 93:148-54.
70. Grebely J, Knight E, Ngai T, et al. Reinfection with hepatitis C virus following sustained virological response in injection drug users. J Gastroenterol Hepatol 2010; 25:1281-4.
71. Grebely J, Pham ST, Matthews GV, et al. Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. Hepatology 2012; 55:1058-69.
72. Sarrazin C, Hezode C, Zeuzem S, Pawlotsky JM. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012; 56(Suppl 1):S88-100.
73. Martin NK, Vickerman P, Grebely J, et al. HCV treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals [Epub ahead of print]. Hepatology 2013; doi:10.1002/hep.26431.
74. Feinstone SM, Hu DJ, Major ME. Prospects for prophylactic and therapeutic vaccines against hepatitis C virus. Clin Infect Dis 2012; 55(Suppl 1):S25-32.
75. Lindenburg CE, Lambers FA, Urbanus AT, et al. Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project. Eur J Gastroenterol Hepatol 2011; 23:23-31.
76. Senn O, Seidenberg A, Rosemann T. Determinants of successful chronic hepatitis C case finding among patients receiving opioid maintenance treatment in a primary care setting. Addiction 2009; 104:2033-8.
77. Harris KA Jr, Arnsten JH, Litwin AH. Successful integration of hepatitis C evaluation and treatment services with methadone maintenance. J Addict Med 2010; 4:20-6.
78. Hallinan R, Byrne A, Agho K, Dore GJ. Referral for chronic hepatitis C treatment from a drug dependency treatment setting. Drug Alcohol Depend 2007; 88:49-53.
79. Cullen BL, Hutchinson SJ, Cameron SO, et al. Identifying former injecting drug users infected with hepatitis C: an evaluation of a general practice-based case-finding intervention. J Public Health (Oxf) 2012; 34:14-23.
80. Drainoni ML, Litwin AH, Smith BD, et al. Effectiveness of a risk screener in identifying hepatitis C virus in a primary care setting. Am J Public Health 2012; 102:e115-21.
81. Litwin AH, Smith BD, Drainoni ML, et al. Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk. Dig Liver Dis 2012; 44:497-503.
82. Lloyd AR, Clegg J, Lange J, Stevenson A, et al. Safety and effectiveness of a nurse-led outreach program for assessment and treatment of chronic hepatitis C in the custodial setting. Clin Infect Dis 2013; 56:1078-84.
83. Grebely J, Knight E, Genoway KA, et al. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. Eur J Gastroenterol Hepatol 2010; 22:270-7.
84. Larney S, Kopinski H, Beckwith CG, et al. The incidence and prevalence of hepatitis C in prisons and other closed settings: Results of a systematic review and meta-analysis [Epub ahead of print]. Hepatology 2013; doi:10.1002/hep.26387.
85. Lloyd AR, Clegg J, Lange J, et al. Safety and effectiveness of a nurse-led outreach program for assessment and treatment of chronic hepatitis C in the custodial setting. Clin Infect Dis 2013; 56:1078-84.
86. Post JJ, Arain A, Lloyd A. Enhancing assessment and treatment of HCV infection in prisons. Clin Infect Dis 2013; 57(Suppl 2):S70-4.
87. Doab A, Treloar C, Dore GJ. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Clin Infect Dis 2005; 40(Suppl 5): S313-20.
88. Stein MD, Maksad J, Clarke J. Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. Drug Alcohol Depend 2001; 61:211-5.
89. Walley AY, White MC, Kushel MB, Song YS, Tulsky JP. Knowledge of and interest in hepatitis C treatment at a methadone clinic. J Subst Abuse Treat 2005; 28:181-7.
90. Fischer B, Vasdev S, Haydon E, Baliunas D, Rehm J. [Willing to undergo hepatitis C treatment in a sample of injection drug users in Toronto, Canada]. Presse Med 2005; 34:1209-12.
91. Grebely J, Genoway KA, Raffa JD, et al. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend 2008; 93:141-7.
92. Wolfe D, Carrieri MP, Shepard D. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet 2010; 376:355-66.
93. Vickerman P, Martin N, Turner K, Hickman M. Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. Addiction 2012; 107:1984-95.
94. Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modelling the impact of antiviral treatment, needle and syringe programmes, and opiate substitution therapy. Clin Infect Dis 2013; 57(Suppl 2):S39-45.
95. Martin NK, Vickerman P, Miners A, et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology 2012; 55:49-57.